Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T17:56:58.490Z.
Calculation as of: 2026-10-06T17:56:58.490Z.
Quote observation: 2026-10-06T17:55:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc00e8cb63dba40c56ed5fb80588e73c180b52fe93b8081d2416c5f575d95e45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$112.69M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.92M
EV/FCF Ratio
N/A
TTM Avg
1.44x
3Y Avg
1.44x
5Y Avg
1.44x
Market Cap
$112.81M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $112.69M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $111.92M | N/A | 1.44x | 1.44x | 1.44x |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.81M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A | N/A | N/A | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.02M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.55M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.57M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $109.74M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.70M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.53M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
